FilingReader Intelligence
Zhongsheng Pharma subsidiary gets Macau approval for influenza drug
August 21, 2025 at 12:19 PM UTC•By FilingReader AI
Guangdong Zhongsheng Pharmaceutical's subsidiary Zhongsheng Ruichuang Biotech obtained a proprietary medicine registration certificate from Macau's government for Anruiwei tablets.
The drug is described as a global first-in-class RNA polymerase PB2 protein inhibitor for type A influenza, allowing overseas market expansion.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002317•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Guangdong Zhongsheng Pharmaceutical publishes news
Free account required • Unsubscribe anytime